Aim: To evaluate whether β cells continue to undergo death in the later stages of type 1 diabetes (T1D).
decades after diagnosis. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Studies have also shown detectable Cpeptide in a large subset of individuals with longstanding T1D, suggesting the continued presence of β cells. 6, 16, 17 However, it is unclear whether these persistent cells continue to undergo destruction. 5, 6, 13 Historically, studies of β cell survival have required analysis of histologic samples from donor pancreata. However, histologic staining for β cell death in pancreatic sections from subjects with longstanding T1D has yielded mixed results. 5, 6, 13 These results may be related to inherent limitations of histologic analyses, including heterogeneity within an individual pancreas, and incomplete representation of the entire pancreas, given the limited availability of donor pancreatic sections. A better understanding of the natural history of β cell death in T1D is key to the development of treatment strategies, as well as for monitoring treatment efficacy in T1D.
Because β cells contain substantially increased amounts of unmethylated preproinsulin (INS) DNA compared with other cell populations, DNA release by dying β cells leads to increased circulating levels of unmethylated INS DNA. [18] [19] [20] [21] [22] [23] Thus, in contrast to histologic analyses of β cells, measurement of circulating unmethylated INS DNA provides the opportunity to monitor a marker of β cell death in vivo. 4, 15 This assay was first reported by the Herold group in 2011, based on the idea that circulating DNA released by dying β cells could be detected by measuring differentially methylated CpG dinucleotides in the insulin gene. 18 These initial analyses utilized nested PCR to calculate a demethylation index of circulating unmethylated INS DNA relative to methylated INS DNA, which was increased in serum from mouse models of T1D as well as in human subjects with new onset T1D. 18 Subsequent modifications and variations of this assay have been reported by this group and others, including analysis of CpG sites in the insulin promoter, utilization of dual probe-based detection strategies, use of droplet digital PCR (ddPCR) for absolute quantification of copy numbers, and performance of next-generation sequencing to simultaneously analyse multiple CpG sites. 19, [23] [24] [25] In addition to an increase in the ratio of circulating unmethylated to methylated INS DNA, our group previously described absolute elevations in both serum unmethylated and methylated INS DNA in paediatric subjects with new onset T1D. 20 At the first follow-up visit 8 weeks after diagnosis, during the postdiagnosis honeymoon period, unmethylated INS DNA levels decreased, but methylated INS DNA levels were persistently elevated. 20 While the aetiology of increased methylated INS DNA has not been definitively elucidated in this population, similar increases in circulating cell-free plasma DNA in patients with sepsis point to DNA release by other cell types impacted by systemic immune activation associated with T1D. 26, 27 Cross-sectional analyses of at-risk antibody positive family members of individuals with T1D have also shown increases in unmethylated INS DNA levels, although longitudinal analysis suggested that there is considerable variability in the signal over time, with both normal and abnormal values at different timepoints before progression to T1D. 22, 25 This assay may also provide insights into the therapeutic benefits of T1D treatment or prevention strategies, as unmethylated INS DNA levels were decreased in subjects who received teplizumab (antiCD3 monoclonal antibody) compared with placebo. 28 Patients with T1D receiving cadaveric allogenic islet transplants exhibited increased plasma unmethylated INS DNA levels in the first hours after transplant that declined during the subsequent days after the procedure, consistent with the known loss of islets that occurs during isolation and the initial transplant period. 23 Although the work above has identified elevations in this novel biomarker of β cell death before onset and at diagnosis of T1D, circulating INS DNA levels are not well characterized in the later stages of T1D. 20, 22, 23 To address this unknown, we sought to determine whether continued β cell destruction, as reflected by serum unmethylated INS DNA, occurs in individuals with longstanding T1D participating in the T1D Exchange Registry, a clinic-based registry of individuals with T1D, followed at endocrinology centres throughout the United
States. 29 We quantified copies of fasting serum unmethylated INS DNA using ddPCR, with a dual fluorescent probe-based multiplex assay that detects methylation or unmethylation at bp −69 of the INS gene. We predicted that T1D subjects would have increased unmethylated INS DNA, consistent with ongoing β cell death. 20 To understand the relationship of β cell death with detectable insulin production, we performed measurements in both C-peptide positive and negative subjects. Stimulated samples from a mixed-meal tolerance test (MMTT) were analysed in a subset of individuals to assess any differences induced by carbohydrate challenge.
| SUBJECTS AND METHODS

| Subjects
Frozen serum samples were obtained from the T1D Exchange Biobank of the T1D Exchange Registry. 29 The subjects all had a clinical diagnosis of T1D made by an endocrinologist on the basis of either positive islet cell antibodies or insulin therapy started around the time of diagnosis and used continually thereafter. 16 Samples were obtained from fasting and 90-minutes timepoints of an MMTT, as previously described. 16, 29 Briefly, participants were instructed to fast for 10 hours and hold rapid-acting insulin within 2 hours of testing. A high-protein drink was administered at 6 mL/kg over 5 minutes, with blood sam- Table 1 . Serum from all subjects was stored at −80 C until use. Researchers were blinded to subject characteristics until after assays had been performed.
| Laboratory assays
Values for HbA1c and C-peptide, as well as human leukocyte antigen (HLA)-DRB1 typing, fasting glucose and autoantibodies against glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2) and Zinc Transporter 8 (ZnT8) were measured by the Type 1 Diabetes Exchange study as previously described. 16, 29 HLA DRB1*04:01, DRB1*0402, DRB1*4:05, and DRB1*03:01 were considered high-risk alleles.
Concentrations of unmethylated and methylated INS DNA were assayed in fasting and 90-minutes serum samples from all subjects.
The assay for serum unmethylated and methylated INS DNA using ddPCR has previously been described. 20, 30 Briefly, DNA was extracted from 50 μL of serum using the QiaAmp DNA Blood Mini kit (Qiagen)
with 5 μg of poly-A DNA as carrier. Bisulfite conversion was performed using the EZ DNA Methylation-Lightning Kit (Zymo Research).
Samples were analysed by ddPCR using a dual fluorescent probebased multiplex assay. The following primers were used: 
| Statistical analysis
To address non-normal distributions of subject variables and INS DNA values, medians and interquartile ranges (IQRs) were calculated and compared between groups using Wilcoxon Rank Sum tests or, for >2
groups, a Kruskal-Wallis test with Dunn's multiple comparisons test.
Differences among categorical demographic variables were tested using Chi-square tests. Spearman correlations were used to measure monotonic relationships between INS DNA levels and other key variables. GraphPad Prism Version 6.00 (GraphPad Software) was used for statistical analyses of sample data. For all analyses, a p value of ≤0.05 was considered significant.
| RESULTS
Baseline characteristics of the participants are shown in Table 1 .
Median ages of C-peptide negative and positive subjects were 34 years (IQR: 23.5, 55) and 32 years (20.5, 47); and median T1D duration was 12 years (5.5, 24.5) and 9 years (4, 16), respectively.
Median HbA1c for both groups was 7.8% (IQR 6.5-8.5 for C-peptide negative and 6.8-9.0 for C-peptide positive subjects). Diabetes comorbidities and complications for T1D subjects are detailed in Table S1 . Nine individuals with T1D were taking other medications besides insulin, which included metformin alone (n = 6), pramlintide acetate (n = 1), liraglutide (n = 1) and metformin + glimepiride (n = 1).
To test whether we could detect persistent evidence of β cell death among individuals with longstanding T1D, we compared serum unmethylated and methylated INS DNA levels between control samples and samples from T1D Exchange subjects. As shown in Figure 1A ,B, compared with controls, we observed increased fasting and stimulated unmethylated INS DNA levels among both C-peptide negative and C-peptide positive T1D subjects, suggesting ongoing β cell death among both groups. Consistent with previous findings of elevations at the time of T1D onset, fasting and stimulated concentrations of methylated INS DNA were also increased in both T1D groups compared with controls ( Figure 1C,D) . 20 Next, we tested whether mixed-meal stimulation had any effects on circulating INS DNA levels. Among all subjects, individual fasting and stimulated INS DNA levels were correlated (r s = 0.48, P < 0.001 No significant relationships were detected between fasting DNA levels and these variables. Serum unmethylated and methylated INS DNA levels are increased in both C-peptide negative and C-peptide positive subjects with longstanding T1D. Fasting and stimulated unmethylated INS DNA (A, B) and methylated INS DNA (C, D) levels were measured among nondiabetic controls and in C-peptide negative (C pep Neg) and C-peptide positive (C pep Pos) subjects with T1D. For fasting samples, n = 54 for controls, 45 for C pep Neg and 45 for C pep Pos subjects. For stimulated samples, n = 12 for controls, 20 for C pep Neg and 45 for C pep Pos subjects; *P ≤ 0.05, **P < 0.01, ***P < 0.001
| DISCUSSION
Although multiple recent studies have identified detectable β cells and insulin production among individuals with established T1D, it remains unclear whether β cell death continues to occur during this period. [4] [5] [6] 13, 16, 17 A group of 11 subjects with longstanding T1D were previously noted to have low levels of unmethylated INS DNA, but this analysis was performed using a ratio with a less sensitive, first generation INS DNA assay, in contrast to the current analysis, which was performed with ddPCR to calculate absolute copies of both unmethylated and methylated INS DNA in 90 subjects with T1D. 28 Here we report the novel finding of elevated circulating unmethylated and methylated INS DNA among subjects with longstanding T1D, compared with non-diabetic adult controls. Our results suggest that β cell death may be actively ongoing years after T1D diagnosis. Surprisingly, we detected similar elevations among subjects with and without detectable C-peptide secretion, suggesting that INS DNA concentrations may provide additional information beyond measures associated with β cell function alone.
Elevations in unmethylated INS DNA observed in our samples
were not as pronounced as those previously shown in paediatric subjects with new onset T1D. 20 Our observed serum unmethylated INS DNA values were more comparable with reported values 1 year after T1D diagnosis. 20 Additionally, we did not detect a relationship between T1D duration and unmethylated INS DNA levels. These findings could reflect that only low levels of ongoing β cell death persist after the initial postdiagnosis period, similar to slower rates of C-peptide loss observed after the first year postdiagnosis. 31 Similarities in unmethylated INS DNA levels between C-peptide negative and C-peptide positive individuals could reflect a balance between higher β cell mass in C-peptide positive individuals, but more severe disease and therefore increased residual β cell death in C-peptide negative individuals. Recent work has identified β cell subpopulations that are resistant to immune attack and exhibit characteristics of dedifferentiation and dysfunctional insulin release. 32 Along these lines, our findings could also reflect a relative predominance of a persistent dysfunctional β cell subpopulation that is relatively resistant to autoimmune destruction. Future work is indicated to determine if such a population of cells could be utilized for strategies aiming to regenerate β cell mass in individuals with undetectable serum C-peptide. 33 We also found that unmethylated INS DNA levels were actually reduced among subjects with one or two high-risk HLA-DRB1 alleles compared with subjects without high-risk HLA alleles. This finding could potentially reflect heterogeneity in the T1D course, with high- Mixed-meal stimulation reduces INS DNA levels in T1D subjects with high fasting values. Individual changes in fasting and stimulated values among control, C-peptide negative (C pep Neg) and C-peptide positive (C pep Pos) subjects were analysed for (A) unmethylated INS DNA and (B) methylated INS DNA. (C, D): T1D subjects grouped into quartiles (Q) based on fasting DNA levels and change in unmethylated (C) and methylated (D) INS DNA with stimulation were compared with controls; n = 12 for controls, 20 for C pep Neg and 45 for C pep Pos subjects; *P ≤ 0.05, **P < 0.01 risk HLA subjects having disease characterized by early β cell destruction, resulting in reduced β cell mass, and lower INS DNA levels in established disease. 34 Analyses of longitudinal samples from the same individuals will be necessary to truly understand this relationship.
Consistent with prior work, we also detected increased methylated INS DNA levels in T1D subjects. 20 A suggested source of this signal has been other cell types impacted by systemic immune activation associated with T1D. 26, 27 Alternatively, this finding could reflect inflammation of other islet cells or pancreatic acinar tissue, which has been reported in pancreatic sections from T1D donors. 35 Further studies in other sub- Effects of autoantibody and high-risk HLA status on unmethylated INS DNA levels. For all T1D subjects, fasting unmethylated and methylated INS DNA concentrations were plotted based on (A, B) positivity for at least one islet autoantibody as well as (C, D) the presence of one or two high-risk HLA alleles. Unmethylated INS DNA concentrations (C) and methylated INS DNA concentrations (D) based on at high-risk HLA status among all T1D subjects; n = 24 for Ab negative subjects, n = 66 for Ab positive subjects; n = 19 for subjects without a high-risk HLA, n = 71 for subjects with one or two high-risk HLAs present; **P < 0.01 Correlations of INS DNA levels with demographic variables: Among all subjects, association between T1D duration and fasting (A) unmethylated and (B) methylated INS DNA levels; n = 90 for all subjects and n = 45 for C-peptide negative subjects
We considered the possibility that this result could represent a regression to the mean, or increased variability among subjects with the T1D exchange C-peptide measurements were performed using the TOSOH immunoassay, which has a limit of detection of 17 pmol/L. 16 Although more sensitive C-peptide assays exist, this assay has been widely used by multiple large-scale T1D clinical research networks. 29, [36] [37] [38] Furthermore, subjects with undetectable stimulated C-peptide using the TOSOH assay would probably fall into the "insulin microsecretor" category, with very low C-peptide measurements using ultrasensitive C-peptide assays. Based on this, these individuals would theoretically have smaller numbers of β cells, and therefore lower concentrations of INS DNA if levels were closely linked to circulating C-peptide. By contrast, INS DNA levels were similar among C-peptide negative and C-peptide positive T1D subjects.
There were differences in sex and race among our controls compared with T1D subject groups. However, INS DNA concentrations were not different when compared by sex or race within either control or T1D subject groups, and values for our controls were consistent with previously reported adult control values. 39 Children diagnosed with T1D have consistently been shown to have a more severe disease course than adults, with increased rates of C-peptide loss postdiagnosis. [40] [41] [42] [43] Because a significant portion of our population were diagnosed as adults, these subjects theoretically could have a larger remaining β cell mass and therefore higher circulating unmethylated INS DNA levels. However, we were unable to detect any relationships between age of diagnosis and circulating INS DNA concentrations, which makes this explanation for our findings improbable. Future studies including larger numbers of subjects diagnosed as children are indicated.
Notwithstanding these limitations, our results suggest that low levels of β cell death may persist in subjects with longstanding T1D, independent of residual C-peptide secretion. These findings not only contribute 
